Central Pacific Bank Trust Division Makes New $615,000 Investment in Madrigal Pharmaceuticals, Inc. $MDGL

Posted by Stanley Muller on Aug 6th, 2026

Central Pacific Bank Trust Division purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,145 shares of the biopharmaceutical company’s stock, valued at approximately $615,000.

Several other hedge funds also recently modified their holdings of MDGL. Flagship Harbor Advisors LLC bought a new position in Madrigal Pharmaceuticals in the fourth quarter valued at about $29,000. Kemnay Advisory Services Inc. acquired a new stake in Madrigal Pharmaceuticals during the 4th quarter worth approximately $39,000. Quarry LP acquired a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Johnson Financial Group Inc. acquired a new position in shares of Madrigal Pharmaceuticals during the third quarter worth $50,000. Finally, Accent Capital Management LLC grew its stake in shares of Madrigal Pharmaceuticals by 64.9% in the fourth quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 37 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

Positive Sentiment: Wolfe Research upgraded MDGL to “Outperform” from “Peer Perform” and set a $605 price target. The target implies approximately 17.7% potential upside from the referenced price, signaling increased confidence in Madrigal’s commercial outlook and supporting investor sentiment. Benzinga report
Positive Sentiment: HC Wainwright raised its 2026 earnings forecasts. The firm now expects third-quarter 2026 EPS of $(0.10), versus $(1.05) previously, and fourth-quarter EPS of $0.85, versus $0.18. Its full-year 2026 forecast also improved to $(4.47) from $(7.07), while maintaining a “Buy” rating. These revisions suggest analysts expect Madrigal’s business to approach profitability faster than previously anticipated. MarketBeat analyst estimates
Positive Sentiment: A recent analysis described the launch environment for semaglutide as manageable and Madrigal’s pipeline strategy as disciplined. The view that the company can navigate competition from semaglutide while concentrating resources on its core opportunities may be reassuring to investors evaluating long-term growth and execution risk. Seeking Alpha analysis
Neutral Sentiment: HC Wainwright continues to project a transition from losses in 2026 to positive EPS beginning in 2027, but its estimates remain dependent on successful commercialization and future execution.
Negative Sentiment: HC Wainwright reduced its longer-term EPS estimates. Forecasts were lowered for 2027 through 2030, including 2027 EPS to $8.32 from $11.78 and 2030 EPS to $77.98 from $93.68. Although the firm remains bullish, the cuts temper the valuation upside implied by the revised near-term estimates.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 31st. Truist Financial raised their price target on shares of Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Barclays reduced their price objective on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Bank of America lowered their target price on shares of Madrigal Pharmaceuticals from $550.00 to $542.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Fifteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $689.93.

View Our Latest Stock Report on Madrigal Pharmaceuticals

Insider Activity at Madrigal Pharmaceuticals

In related news, Director Richard S. Levy sold 5,682 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $515.44, for a total transaction of $2,928,730.08. Following the sale, the director directly owned 22,015 shares in the company, valued at approximately $11,347,411.60. The trade was a 20.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the sale, the insider directly owned 10,033 shares in the company, valued at $4,973,759.42. This trade represents a 9.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 7,568 shares of company stock worth $3,880,711. Insiders own 17.60% of the company’s stock.

Madrigal Pharmaceuticals Trading Up 1.3%

Shares of Madrigal Pharmaceuticals stock opened at $514.12 on Thursday. The company has a current ratio of 3.20, a quick ratio of 2.94 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $11.88 billion, a P/E ratio of -39.89 and a beta of -1.01. The stock has a fifty day simple moving average of $515.17 and a 200 day simple moving average of $499.03. Madrigal Pharmaceuticals, Inc. has a 12-month low of $331.00 and a 12-month high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.68) by $0.69. The firm had revenue of $364.25 million for the quarter, compared to the consensus estimate of $352.13 million. Madrigal Pharmaceuticals had a negative return on equity of 56.65% and a negative net margin of 25.32%.The company’s revenue was up 71.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.90) EPS. On average, sell-side analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.03 earnings per share for the current fiscal year.

About Madrigal Pharmaceuticals

(Free Report)

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.